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Introduction: Current therapy for small-cell lung cancer (SCLC) relies 
on chemoradiation therapy, and the role of primary surgical resection 
in these patients remains controversial. A minority of SCLC patients 
present without metastatic disease and are candidates for surgery. This 
study investigates the role of surgical resection in select patients with 
SCLC, using a national cohort of approximately 2500 resected patients.
Methods: A retrospective study of SCLC patients in the National 
Cancer Data Base (NCDB) was performed where patients were 
grouped for comparison by stage and treatment regimen. Survival 
was estimated by Kaplan–Meier methods and multivariate compari-
sons using Cox regression.
Results: Of 28,621 cases of potentially resectable SCLC, 2476 
patients (9%) underwent surgery of the primary site with curative 
intent. Five-year overall survival for patients after resection was 51%, 
25%, and 18% for clinical stages I, II, and IIIA, respectively. Addition 
of surgery to chemotherapy was associated with decreased likelihood 
of death (hazard ratio: 0.57, 95% confidence interval: 0.47–0.68), 
independent of age, stage, and comorbidity score. Lobectomy was 
associated with a 5-year overall survival of 40% compared with 21% 
and 22% for sublobar resection and pneumonectomy, respectively. 
Hazard ratio for death after sublobar resections compared with lobec-
tomy was 1.38 (95% confidence interval: 1.12–1.71).
Conclusions: Patients with stages I, II, and III SCLC, who under-
went surgical resection as part of initial treatment with chemotherapy 
had respectable OS. These data may warrant prospective studies of 
including surgery in the multimodality treatment of SCLC in specific 
circumstances.
Key Words: Small-cell lung cancer, Surgery, Chemotherapy, 
Radiation therapy, Lobectomy, Sublobar resection.
(J Thorac Oncol. 2015;10: 316–323)
Small-cell lung cancer (SCLC) represents approximately 15% of all lung cancers, and 30,000 new diagnoses are 
made annually in the US.1 SCLC often presents with rapid 
growth and early metastasis and consequently is also asso-
ciated with a poor overall prognosis.2 Select patients that 
present without distant metastasis and have disease confined 
to the ipsilateral chest are considered occasionally for curative 
intent resections, but their frequency are relatively rare. SCLC 
is highly sensitive to chemotherapy and radiation therapy, 
but local recurrences are reported as high as 50% in limited 
stage disease.3,4 Several studies have investigated the role of 
surgery combined with chemotherapy and radiation therapy 
to improve local recurrence rates, but to mixed results.5–7 
Currently, the American College of Chest Physicians rec-
ommends surgery only in select stage I patients;8 however, 
over the past 15 years, the use of surgery to treat SCLC has 
extended beyond this stage and thus remains controversial and 
without clear guidelines.
To investigate curative intent resections in a large 
national registry cohort, we defined potentially resectable dis-
ease as those patients with disease confined to the ipsilateral 
hemithorax and without evidence of distant disease. The pur-
pose of this study was to analyze the prevalence of surgery for 
the primary site in patients with potentially resectable SCLC, 
to identify characteristics of patients who may benefit from 
surgery compared with patients treated with traditional regi-
mens of systemic chemotherapy, and to compare different sur-
gical procedures.
METHODS
Patient data was culled from the National Cancer Data 
Base (NCDB), a joint program of the American College of 
Surgeons Commission on Cancer and the American Cancer 
Society. The database contains approximately 26 million 
patients from more than 1500 participating institutions, and 
captures approximately 70% of newly diagnosed cancers in 
the United States annually.9 Standardized collection and defi-
nition of data items has been previously described.10,11 The 
NCDB collects data on patient and hospital characteristics, 
cancer diagnosis, staging, treatments, and outcomes. The data 
used in this study are derived from a deidentified NCDB file. 
The American College of Surgeons and the Commission on 
Cancer have not verified and are neither responsible for the 
analytic or statistical methodology employed nor the conclu-
sions drawn from these data by the investigators.
The study population included patients 18 years of age or 
older with no other history of malignancy diagnosed between 
1998 and 2011. Patients were restricted to histologic diagno-
sis of invasive small-cell bronchogenic carcinoma confirmed 
by microscopic examination of tissue specimen or cytologic 
specimen, and International Classification of Diseases for 
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Oncology, Third Edition (ICD-0–3) codes 8041 to 8044. To 
keep the relatively large data set pure, these criteria do not 
include patients with mixed NSCLC–SCLC histologies, such 
as small cell–large cell, small cell–adenocarcinoma, and small 
cell–squamous cell carcinoma nor NSCLC with neuroendo-
crine features. Clinical and pathological stages are reported 
according to the 7th edition of AJCC’s tumor, node, metasta-
ses (TNM) staging criteria. Patients initially staged using the 
fifth or sixth editions in the NCDB were restaged using all 
available data on tumor characteristics recorded according 
to the AJCC-sponsored Collaborative Stage Data Collection 
System.12 SCLC cases not originally staged under the seventh 
edition that were missing information allowing for restaging 
to the seventh edition were excluded.
Because the primary aim of this study was to evaluate 
outcomes related to surgical treatment of the primary site per-
formed with curative intent, patients with evidence of meta-
static disease, bilateral or midline only tumors, malignant 
pleural or pericardial effusions, lack of identifiable primary 
tumor (T0 or T occult), or clinical T4 and clinical N3 dis-
ease were excluded. To compare treatment groups, patients 
with unknown or undefined treatment history were excluded, 
including unknown chemotherapy or radiation therapy status, 
and surgical procedures such as “excision, NOS” and “resec-
tion, NOS.”
Patients were compared in two treatment groups: pri-
mary surgical treatment and nonsurgical treatment. Patients 
treated with chemotherapy with or without radiation therapy, 
but without surgery, comprised the nonsurgical treatment 
group. Chemotherapy was defined by single- or multi-agent 
systemic chemotherapy as part of the first course of treat-
ment. Radiation therapy was defined by beam radiation as part 
of the first course of treatment to a minimum dose of 45Gy, 
and patients with anatomic target volumes outside the thorax 
were not included in the radiation subgroup. The NCDB does 
not systematically record use of prophylactic cranial irradia-
tion, so this information was not incorporated in this analysis. 
Patients who received chemotherapy or radiation therapy for 
palliation were not included in these groups.
The primary surgical treatment group included all 
patients who underwent resection of the primary site, and 
procedures were defined as sublobar resection, lobectomy, 
and pneumonectomy. Sublobar resections included wedge 
resections and segmental resections. Bronchial sleeve resec-
tions and bilobectomies were grouped under the lobectomy 
category. Surgery performed more than 180 days after diag-
nosis, patients who underwent surgical resection for pal-
liation, and noncurative procedures, such as local tumor 
destruction and laser excision, were excluded from the sur-
gery group. Treatment regimens for patients in the primary 
surgical treatment group were determined using NCDB codes 
for chemotherapy–surgery and radiation–surgery sequences. 
For patients without sequence codes, the number of days from 
diagnosis to definitive or first surgery and start of chemother-
apy or radiation were used to calculate treatment sequences. 
Patients included in an unknown sequence group represent 
those who received both surgery and chemotherapy, but did 
not have dates of treatment or sequence codes.
The primary outcome of interest was the effect of sur-
gical resection of the primary site on overall survival (OS). 
Disease-specific survival is not captured in the NCDB and, 
therefore, was not assessed. OS was estimated by the non-
parametric Kaplan–Meier method and statistical differences 
between strata were evaluated using the log-rank test. Only 
clinical staging was used to compare surgical and nonsurgi-
cal patients. A multivariable Cox proportional hazards model 
with backward elimination of covariates with a p value greater 
than 0.05 was used to control for patient and tumor character-
istics (age, sex, facility type, Charlson–Deyo score, location 
of tumor, laterality, clinical or pathologic T stage, N stage, 
and TNM stage) when evaluating the association of treatment 
with OS. Cox models were repeated with and without vari-
ables missing greater than 10% of patient data. To allow 5 
years of follow-up for all patients before last data collection in 
2011, all survival analysis was limited to patients diagnosed 
from 1998 to 2006. Patients alive at the end of the study were 
censored observations.
All statistical tests and analyses were performed using 
SAS v9.1 (SAS Institute, Cary, NC). p value less than 0.05 
was used as the threshold for statistical significance.
RESULTS
Of 203,229 staged patients with histologic confirma-
tion of SCLC, 35,927 (18%) met initial criteria for potentially 
resectable disease. Of these patients, 28,621 had documented 
surgical or systemic treatment and were included in further 
analysis. Median age was 66 years (range, 23–90). Patient 
data by treatment group are shown in Table 1.
Of the 2476 patients in the primary surgical treatment 
group, lobectomy was the most common procedure compris-
ing 71% (n = 1749) of the surgical cohort. Twenty-four percent 
of patients (597) underwent a sublobar resection, the major-
ity of which were wedge resections (535), whereas only 5% 
patients (130) had a pneumonectomy. Eighty-seven percent of 
patients (2158) had negative microscopic surgical margins by 
surgical pathology. Regional node surgery predominated with 
92% of patients (2291) with recorded nodal surgery status at 
primary resection. The majority of surgical patients received 
chemotherapy, 68% (1679), and 20% (501) received radia-
tion therapy in addition to surgery. Treatment regimens for the 
primary surgical and nonsurgical treatment groups are shown 
in Table 2. Of 1402 surgical patients with a recorded clinical 
stage, 77% of patients (1085) had the same pathologic stage, 
4% of patients (50) had a lower pathologic stage, whereas 
19% of patients (267) were upstaged. Fewer than 10 resected 
patients with clinical stages IA–IIIA were upstaged to patho-
logic stage IIIB, the remainder of pIIIB patients did not have 
a recorded clinical stage. Analysis of the patients diagnosed 
in 2007–2011, who lack verified 5-year follow-up and are 
not included in the following survival analysis, revealed an 
increase in the use of surgery in potentially resectable lesions 
to 10% (1008) from 8% for patients (1468) diagnosed before 
2007 (p < 0.0001). In these resected patients, there was an 
increase in the frequency of sublobar resections compared 
with lobectomy, from 22% (323) to 27% (274), (p = 0.0192), 
whereas the incidence of pneumonectomy decreased from 7% 
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TABLE 1.  Patient and Tumor Characteristics for SCLC Patients by Treatment Group
Variable Level Primary Surgical Treatment % (n) Nonsurgical Treatment % (n) Total, n
Age <60 26 (638) 27 (6948) 7586
60–75 59 (1457) 56 (14,665) 16,122
Over 75 15 (381) 17 (4532) 4913
Sex Men 45 (1111) 46 (11,980) 13,091
Women 55 (1365) 54 (14,165) 15,530
Charlson–Deyo 0 34 (848) 39 (10,306) 11,154
Scorea 1 27 (666) 17 (4462) 5128
2+ 10 (256) 7 (1822) 2078
Not recorded 29 (706) 37 (9555) 10,261
Clinical TNM stage IA 34 (841) 9 (2224) 3065
IB 7 (168) 6 (1660) 1828
IIA 8 (192) 11 (2863) 3055
IIB 2 (43) 6 (1689) 1732
IIIA 6 (158) 64 (16,848) 17,006
Not recorded 43 (1074) 3 (861) 1935
Clinical T stage cT1 50 (1232) 29 (7640) 8872
cT2 22 (538) 44 (11,536) 12,074
cT3 4 (88) 25 (6572) 6660
Not recorded 25 (618) 2 (397) 1015
Clinical N Stage cN0 37 (909) 22 (5816) 6725
cN1 8 (197) 13 (3441) 3638
cN2 6 (144) 61 (15,965) 16,109
Not recorded 50 (1226) 4 (923) 2149
Laterality Origin of primary is right 54 (1332) 59 (15,367) 16,699
Origin of primary is left 46 (1144) 41 (10,778) 11,922
Primary site Upper lobe 58 (1439) 57 (14,950) 16,389
Middle lobe 6 (146) 6 (1488) 1634
Lower lobe 33 (814) 26 (6724) 7538
Overlapping lesion 1 (26) 2 (536) 562
Not specifiedb 2 (51) 9 (2447) 2498
Facility type Community Cancer Program (CCP) 11 (276) 15 (3817) 4093
Comprehensive CCP 57 (1410) 61 (16,042) 17,452
Academic/research program 31 (763) 22 (5774) 6537
Other specified cancer programs 1 (27) 2 (512) 539
Year of diagnosis 1998–2002 29 (706) 37 (9555) 10,261
2003–2006 31 (762) 28 (7259) 8021
2007–2011 41 (1008) 36 (9331) 10,339
Pathologic TNM stage IA 38 (953)
IB 13 (334)
IIA 22 (553)
IIB 5 (119)
IIIA 20 (483)
IIIB 1 (34)
Pathologic T stage pT1 58 (1424)
pT2 32 (787)
pT3 8 (188)
pT4 3 (77)
Pathologic N stage pN0 58 (1430)
pN1 25 (617)
pN2 17 (417)
Not recorded <1 (12)
aOnly recorded for patients diagnosed from 2003 to 2011.
bLung, not otherwise specified.
SCLC, small-cell lung cancer; TNM, tumor, node, metastases.
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(103) to 3% (27) after 2006 (p < 0.0001). Diagnosis of SCLC 
and definitive surgery were recorded as the same day for 41% 
of patients (826), indicating these patients likely underwent 
surgery without pathologic diagnosis of SCLC.
Including only the patients diagnosed before 2007, 88% 
of patients (16,175 of 18,282) died, with a median survival 
of 15.9 months. Unadjusted Kaplan–Meier analysis showed 
significant differences in 5-year OS by treatment group in 
all clinical stages, with surgery plus chemotherapy having 
the best OS (Fig. 1). For these patients, 5-year OS was 51%, 
25%, and 18% for clinical stages I, II and III, respectively. In 
analysis of stage A and B subgroups, clinical stage IA patients 
had the best survival, with 5-year OS of 54% after resection 
plus nonsurgical therapy compared with 18% after nonsurgi-
cal therapy (p < 0.0001). For clinical stage IB patients, sur-
gery with chemotherapy had a 5-year OS of 36%, whereas 
survival after nonsurgical therapy was 19% (p = 0.009), simi-
lar to stage IA patients treated in the same fashion. For clini-
cal stage IIA patients treated with surgery and chemotherapy, 
5-year OS was 24%, whereas chemotherapy alone was asso-
ciated with 5-year OS of 17%. Survival differences between 
treatment groups were not significant when 33 clinical stage 
IIB patients were analyzed separately (p = 0.139), with fewer 
than 10 patients undergoing both surgery and chemotherapy. 
In clinical stage IIIA patients, 5-year OS was 12% for nonsur-
gical therapy alone and 18% with the addition of surgery (p 
= 0.047, Fig. 1C). Analysis by Charlson–Deyo comorbidity 
score showed that patients treated with surgery and nonsurgi-
cal therapy had significantly improved survival, with 5-year 
OS of 43%, 40%, and 25% for comorbidity scores of 0, 1, 
and 2+ (p < 0.0001, Fig. 2). Among primary surgical patients, 
lobectomy was associated with an OS of 40%, compared with 
21% and 22% for sublobar resections and pneumonectomy, 
respectively (p < 0.0001, Fig. 3). When comparing only patho-
logic stage I patients, 5-year OS was 49% after lobectomy ver-
sus 30% after a sublobar resection. Kaplan–Meier curves for 
patients who underwent lobectomy are shown by pathologic 
stage in Figure 4. For comparison, 5-year OS was 5% for both 
patients with metastatic or otherwise nonresectable disease 
at diagnosis (n = 122,484), as well as patients with poten-
tially resectable disease, who received neither surgery nor 
chemotherapy (n = 3408). Although these groups may illus-
trate the natural history of SCLC, they represent an alternative 
treatment paradigm and were not included in our analysis.
TABLE 2.  Frequency of Treatment Regimens among Patient 
Groups
Treatment Regimens Total % (n)
Primary surgical treatment (n = 2476)
  Neoadjuvant chemoradiation (CR-S) <1 (12)
  Neoadjuvant chemotherapy (C-S) 2 (40)
  Adjuvant chemotherapy (S-C) 45 (1106)
  Surgery without chemotherapy (S) 32 (796)
  Adjuvant chemoradiation (S-CR) 17 (409)
  Surgery with chemotherapy, unknown sequence 5 (113)
Nonsurgical treatment (n = 26,145)
  Chemotherapy only 45 (11,661)
  Chemoradiation 55 (14,484)
CR, chemoradiation therapy; C, chemotherapy; S, surgery.
FIGURE 1.  Kaplan–Meier curve for overall survival by clinical 
stage I (A), II (B), and IIIA (C) patients by treatment, including 
NST, surgery alone, or surgery with NST (Surg + NST). NST, 
nonsurgical therapy.
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When controlling for patient and tumor characteris-
tics, independent predictors of survival included age, sex, 
stage, and Charlson–Deyo Score (Table 3). For patients who 
received chemotherapy, hazard ratio (HR) was lower for those 
who also underwent surgery compared with those who were 
treated with nonsurgical therapy alone (HR: 0.57, 95% confi-
dence interval: 0.47–0.68). In the primary surgical treatment 
group, improved outcomes were associated with adjuvant 
chemotherapy sequences when compared with surgery alone 
(Table 3). When procedure types were compared, sublobar 
resection was significantly associated with increased likeli-
hood of death compared with lobectomy (HR: 1.38, 95% 
confidence interval: 1.12–1.71). Charlson–Deyo score was 
not collected for patients diagnosed before 2003 (56%). Both 
models were rerun without Charlson–Deyo score to include 
patients diagnosed before 2003, and there were no changes in 
the predicting factors or trends (data not shown). The models 
shown incorporate the comorbidity score for completeness.
DISCUSSION
SCLC is a rapidly progressive malignancy with a median 
survival of 17 months and 5-year OS of 10% for approximately 
FIGURE 2.  Kaplan–Meier curve for overall survival by 
Charlson–Deyo score of 0 (A), 1 (B), and 2+ (C) by treatment, 
including NST, surgery alone, or surgery with NST (Surg + 
NST). NST, nonsurgical therapy.
FIGURE 3.  Kaplan–Meier curve for overall survival of primary 
surgical treatment patients by type of surgical procedure.
FIGURE 4.  Kaplan–Meier curve for overall survival of lobec-
tomy patients by pathologic stage.
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40% of patients who present with nonmetastatic disease.13,14 
Current therapies for most patients include platinum-based 
chemotherapy, with or without radiation, but the role of 
surgery in treatment of SCLC remains controversial, as the 
disease is typically treated as systemic, even without clini-
cal evidence of metastatic disease. This analysis represents a 
highly select group of patients with early diagnosis of SCLC, 
and the inherent selection bias of patients who are candidates 
TABLE 3.  Cox Proportional Hazards for Mortality for Overall Cohort and Primary Surgical Treatment Group
Characteristic Hazard Ratio 95% CI p Value
Overall cohort
  Age (ref = <60)
   60–75 1.28 1.20–1.36 <0.0001
   Over 75 1.87 1.72–2.03 <0.0001
  Sex (ref = men)
   Female 0.85 0.81–0.90 <0.0001
  Charlson–Deyo score (ref = 0)
   1 1.31 1.23–1.39 <0.0001
   2+ 1.56 1.43–1.71 <0.0001
  Clinical T Stage (ref = cT1)
   cT2 1.19 1.11–1.27 <0.0001
   cT3 1.30 1.21–1.39 <0.0001
  Clinical N Stage (ref = cN0)
   N1 1.12 1.02–1.23 0.0138
   N2 1.38 1.29–1.47 <0.0001
  Treatment (ref = chemotherapy only)
   Surgery + chemotherapy 0.57 0.47–0.68 <0.0001
   Surgery only 0.95 0.75–1.21 0.6731
Primary surgical treatment group
  Age (ref = <60)
   60–75 1.61 1.27–2.05 <0.0001
   Over 75 2.47 1.85–3.3 <0.0001
  Charlson–Deyo score (ref = 0)
   1 1.04 0.85–1.28 0.692
   2+ 1.76 1.34–2.3 <0.0001
  Primary tumor site (ref = upper lobe)
   Lower lobe 1.36 1.13–1.65 0.002
   Middle lobe 1.51 0.99–2.32 0.057
   Overlapping lesion 4.31 1.96–9.52 0.0003
  Pathologic T Stage (ref = pT1)
   T2 1.19 0.96–1.46 0.106
   T3 1.84 1.32–2.58 0.0004
   T4 1.1 0.62–1.95 0.749
  Pathologic N Stage (ref = pN0)
   N1 2.21 1.75–2.79 <0.0001
   N2 2.7 2.05–3.56 <0.0001
  Treatment sequence (ref = surgery only)
   Neoadjuvant chemoradiation (CR-S) 0.51 0.07–3.71 0.505
   Neoadjuvant chemotherapy (C-S) 0.61 0.31–1.21 0.160
   Adjuvant chemoradiation (S-CR) 0.41 0.31–0.56 <0.0001
   Adjuvant chemotherapy (S-C) 0.53 0.43–0.65 <0.0001
  Surgical procedure (ref = lobectomy)
   Sublobar resection 1.38 1.12–1.71 0.003
   Pneumonectomy 1.22 0.84–1.78 0.297
CI, confidence interval.
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for surgery must be acknowledged when comparing patients 
who underwent resection versus nonsurgical therapy alone. 
Only 18% of patients in this NCDB cohort met criteria for 
potentially resectable disease, and fewer than 10% of these 
patients underwent primary resection with curative intent, 
including sublobar resection, lobectomy, and pneumonectomy.
In this population, the improved survival of potentially 
resectable SCLC patients treated with surgery and chemother-
apy mirrors that of NSCLC patients. NSCLC 5-year OS for 
pathologic stages I, II, and III is 66%, 41%, and 23%, respec-
tively.15 In comparison, SCLC patients treated with multimo-
dality therapy including surgery had survival rates of 49%, 
32%, and 27% for the same pathologic stages, respectively. 
Similar results were noted in the UK population analyzed by 
Lüchtenborg et al.16 who found a 31% 5-year OS in resected 
SCLC of all stages, compared with 45% in resected NSCLC 
patients. When compared with clinical stage, surgical patients 
in this study demonstrated improved survival compared with 
patients of the same clinical stage treated with standard non-
surgical therapy. The rationale for using clinical stage for 
survival analysis was that it allowed for comparisons to the 
majority of patients who are treated without pathologic stag-
ing, i.e., underwent nonsurgical therapy. However, recom-
mendations from the American College of Chest Physicians 
(ACCP) indicate surgical resection only for patients with 
clinical stage I SCLC (T1-2, N0), followed by chemother-
apy.8 The National Comprehensive Cancer Network (NCCN) 
guidelines similarly recommend surgery with adjuvant che-
motherapy only for stage I disease, and specify that lobectomy 
is the preferred resection procedure.17 Stage I surgical patients 
in the SEER database were associated with a range of 5-year 
OS from 34% to 57% depending on type of resection and use 
of radiotherapy, and other stage I studies found an average 
5-year OS of 52%.18 Small groups of only confirmed patho-
logic stage I patients after surgery have demonstrated survival 
ranging from 48% to 86%.19,20 Overall, the use of surgery in 
this population remains low despite evidence and guidelines 
recommending surgery. In this cohort, only 21% of stage I 
patients had surgical resection.
In addition to stage I patients, this investigation indi-
cates that certain patients with clinical stage II and III dis-
ease may also benefit from surgical resection as part of their 
treatment strategy. These data are consistent with an earlier 
report by Schreiber et al.21 showing a 26% 5-year OS for T3/
T4 or N1/N2 SCLC after surgery, compared with 9% among 
similarly staged patients without resection. Additional smaller 
series have demonstrated clear survival benefit for adding sur-
gery in N1 and N2 patients.22,23 Using an earlier NCDB cohort 
from 1992 to 2002, Gaspar et al.24 demonstrated a benefit for 
surgery combined with nonsurgical treatment, compared with 
chemoradiation therapy alone in stage I and II patients (HR: 
2.0), and also in stage III patients (HR: 1.49). This evidence 
suggests that stage II and III patients could be included in fur-
ther studies to identify specific candidates in whom surgical 
therapy may be advantageous.
Few prospective trials have investigated surgical resec-
tion in SCLC. The only published randomized controlled 
trial by the Lung Cancer Study Group in the 1980s did not 
demonstrate a benefit in surgical treatment for SCLC.6 In this 
study, 146 limited stage patients with partial response to induc-
tion chemotherapy were randomized to surgery or no surgery, 
with median survival of 15.4 and 18.6 months, respectively. 
Application of this study to negate a role for surgery has been 
criticized based on the intent to treat model, which included 
over 30% of patients in the surgical arm who did not undergo 
a complete resection. In addition, the study took place before 
widespread use of platinum-based chemotherapy and staging 
mediastinoscopy.21,23 A phase II trial by Eberhardt et al. treated 
46 patients, stages IA–IIIB, with multimodal therapy. After 
induction chemotherapy with or without radiation therapy, 
patients with complete nodal response by a restaging medi-
astinoscopy were eligible for resection. The resection group 
of 23 patients, stage IB–IIIA, had a 5-year OS of 63%, with 
100% local control in completely resected patients, although 
9 patients (36%) had distant recurrence.7
Our data indicate that sublobar resections result in 
worse outcomes than lobectomy, with 5-year OS of 30% and 
49%, respectively, in stage I patients. Across all stages lobec-
tomy patients had a 40% 5-year OS, compared with 21% for 
sublobar resection. In this study, approximately 24% of all 
resected patients (26% of resected stage I patients) underwent 
sublobar resections. Similarly, patients from the SEER data-
base had median survival of 23 months for sublobar resection 
versus 40 months for lobectomy in all limited stage cases, and 
in the subset of stage I patients, lobectomy was superior to 
sublobar resection, with a 5-year OS of 50% and 34%, respec-
tively.18,21 Overall, these findings suggest that sublobar resec-
tion for SCLC may be suboptimal in the treatment of SCLC 
patients whether or not they have a preoperative diagnosis of 
SCLC.
The majority of resected patients also received chemo-
therapy, although 32% underwent resection without additional 
systemic therapy. The most common regimens were adjuvant 
chemotherapy and adjuvant chemoradiation therapy, which 
were both associated with significant benefit in multivariate 
analysis of the surgical group. The surgical studies discussed 
above have included multiple combinations of chemotherapy 
and radiation therapy used in both neoadjuvant and adjuvant 
settings. For some surgical patients, pathologic stage may 
represent downstaging after neoadjuvant therapy. It is unclear 
why about a third of patients did not undergo adjuvant therapy, 
despite NCCN and AJCC guidelines recommending chemo-
therapy in all stages. Further investigation is required to deter-
mine which treatment paradigms optimize survival in each 
stage of SCLC.
Although our investigation was retrospective, it is the 
largest analysis of SCLC patients treated with surgery thus far, 
and accounts for important modifiers that many other studies 
were unable to assess. Limitations of our study include the 
incomplete nature of a large national database and our inabil-
ity to confirm reported data such as staging and treatment. 
Although we selected only cases with pure SCLC histologic 
codes and microscopic confirmation to exclude other patholo-
gies such as carcinoid and mixed NSCLC–SCLC tumors, we 
cannot exclude the possibility that some cases were incor-
rectly diagnosed or recorded. Also, the rationale for why 
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some patients underwent sublobar resections as their surgi-
cal therapy was not explored due to the absence of granular 
information signifying cardiac or pulmonary status such as 
echocardiographic results or pulmonary function testing, 
respectively.
Although this study demonstrates that surgery is asso-
ciated with improved OS in select patients when used as a 
part of multimodality treatment paradigm with chemotherapy 
with or without radiation therapy, local or distant recurrence 
or disease-specific mortality could not be assessed. Thus, the 
uncensored cohort includes patients alive with disease. In 
addition, survival analyses include only patients diagnosed 
before 2007. Finally, the impact of surgical complications and 
their effect on OS or functional recovery was not evaluated. 
We caution readers to interpret the results of this study within 
the context of these limitations, and we expect that future 
investigations will address remaining questions.
Overall, the primary surgical cohort represents a small 
subgroup of SCLC patients who present with a potentially 
resectable primary tumor and no evidence of metastatic dis-
ease. Although the NCDB does not have sufficient data to 
investigate this, the authors speculate that patients selected 
for resection represented a lower risk population who were 
likely to have a better outcome with any mode of therapy, and 
we acknowledge that this enhances the survival differences 
between patients treated with and without surgery. Patients 
selected for resection likely had less tumor burden, higher 
performance status, and less comorbidity. Still, the survival 
benefit for surgical treatment was evident for patients with 
Charlson–Deyo scores of 1 and 2 or higher, and in multivariate 
analysis surgery remained independently predictive of reduced 
mortality. A prospective trial may more clearly identify patient 
and tumor characteristics associated with improved outcome 
after primary resection.
In conclusion, this study supports a role for surgery in 
highly selected patients, including some with stage II and III, 
node positive SCLC. In addition, the data strongly support 
the use of lobar resection for all surgery with curative intent, 
and the eschewing of wedge and other sublobar resections 
for these patients. These data, with over 28,000 patients and 
nearly 2500 surgical cases, may justify additional prospective 
studies to further clarify the role of surgery in SCLC and to 
identify the patients who will benefit from the inclusion of 
primary resections in multimodality therapies.
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